Cheryl Xiang

No ORCID on file · 2 papers in corpus
2020
Author response for "Estimating the effect of elagolix treatment for endometriosis on post‐menopausal bone outcomes: a model bridging registrational phase III trials to an older real‐world population"
·doi:10.1002/jbm4.10401/v2/response1
other 2020
Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population
JBMR plus ·doi:10.1002/jbm4.10401

Elagolix, a gonadotrophin-releasing hormone antagonist, is used in premenopausal women with endometriosis. There is a risk of bone loss with elagolix, but the long-term effects of BMD loss later in life cannot be directly assessed and has n…